Navigation Links
STAAR Surgical's Visian ICL Procedure Performed Live on NBC's Today show
Date:3/4/2008

MONROVIA, Calif., March 4 /PRNewswire-FirstCall/ -- STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, congratulates Dr. Brian Boxer Wachler on his live surgical procedure on NBC's Today Show this morning correcting NBCSports.com columnist Alan Abrahamson's vision with STAAR's Visian ICL lenses.

The Visian ICL is the only foldable, minimally invasive lens approved in the U.S. for the correction of myopia, or nearsightedness, in adults. It can be especially useful in patients such as Abrahamson, who had a high prescription requirement to correct his nearsighted vision. The Visian ICL is approved for myopic patients as low as -3.0 diopters and delivers exceptional clarity and quality of vision.

During the brief procedure, which commonly takes 15 to 20 minutes per eye, Dr. Boxer Wachler made a micro incision to allow positioning of the implant behind the iris and in front of the natural lens. Both eyes were corrected during the show and Abrahamson was asked about any pain during the procedure by Meredith Vieira, co-anchor of the Today Show, to which he responded, "I cannot feel a thing." Before the procedure Abrahamson was unable to see the largest letter on the standard vision chart. Post-operatively, he said he could see "crisply and cleanly." He showed significant improvement instantaneously.

The Today Show segments can be viewed at:

http://www.msnbc.msn.com/id/21134540/vp/23463382#23463382

The implantable Collamer lens has been successfully implanted in over 80,000 eyes worldwide. In an FDA clinical trial, over 99 percent of patients were satisfied with their implant. The Visian ICL has a track record of stable, consistently excellent clinical outcomes. Data from research shows that the Visian ICL has some advantages over refractive surgical procedures such as PRK and LASIK, and has a lower chance of inducing higher order aberrations compared to LASIK. To learn more about the Visian ICL or to locate a certified surgeon in your area you can go to STAAR's consumer website: http://www.staar.com/html/visian-icl.html

About the VISIAN ICL

Made of a highly biocompatible Collamer(R) material containing a small amount of collagen, the Visian ICL's unique lens design allows for a minimally invasive procedure and an aesthetically pleasing outcome, because the lens is placed behind the iris. Unlike laser vision procedures the Visian ICL corrects vision without permanently altering the structure of the eye and can be removed if needed.

Doctors familiar with the technology have noted the ICL's stability, the safety of the procedure, superior clinical outcomes and high patient satisfaction rate. The Visian ICL is a refractive phakic implant intended for placement in the posterior chamber of the eye. The approved models are indicated for the correction of myopia in adults with myopia ranging from -3.0 to less than or equal to -15.0 diopters, with astigmatism less than or equal to 2.5 diopters at the spectacle plane, and the reduction of myopia in adults with myopia ranging from greater than -15.0 to -20.0 diopters with astigmatism less than or equal to 2.5 diopters at the spectacle plane, in patients 21 to 45 years of age with anterior chamber depth (ACD) 3.00 mm or greater, and a stable refractive history within 0.5 diopters for one year prior to implantation.

About STAAR Surgical

STAAR is a leader in the development, manufacture and marketing of minimally invasive ophthalmic products employing proprietary technologies. STAAR's products are used by ophthalmic surgeons and include the Visian ICL, a tiny, flexible lens implanted to correct refractive errors, as well as innovative products designed to improve patient outcomes for cataracts and glaucoma. The ICL is approved by the FDA for use in treating myopia, has received CE Marking and is sold in more than 40 countries. More information is available at http://www.staar.com.

CONTACT: Investors

EVC Group

Douglas Sherk, 415-896-6820

Matthew Selinger, 415-896-6817

Media

EVC Group

Steve DiMattia, 646-277-8706

Christopher Gale, 646-201-5431


'/>"/>
SOURCE STAAR Surgical Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. STAAR Surgical Reports Operational Progress
2. STAAR Surgical Announces Third Quarter 2007 Earnings Release Date and Conference Call
3. STAAR Surgical to Purchase Canons Interest in Japanese Joint Venture
4. STAAR Surgical Reports Third Quarter Results
5. Barry G. Caldwell Named Chief Executive Officer of STAAR Surgical
6. STAAR Surgical to Present at the BMO Capital Markets Focus on Healthcare Conference
7. STAAR Surgical Completes $5M Debt Financing for Purchase of Japanese Joint Venture
8. STAAR Surgical to Present at the Tenth Annual Needham Growth Conference
9. STAAR Surgical Announces Fourth Quarter and Full Year 2007 Earnings Release Date and Conference Call
10. UK junior doctors gaining less experience of common procedures
11. New male sling procedure helps prostate cancer survivors who suffer from urinary incontinence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica ... in thought leadership , media relations, social media, content marketing and SEO, ... be powered through Act-On, an intuitive marketing automation platform. , Rosica will now ...
(Date:2/23/2017)... ... 23, 2017 , ... On February 22, 2017 the U.S. ... to withdraw previous guidance issued by the Obama Administration requiring schools to treat ... 2016 by the Obama Administration came in response to a growing number of ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The American Cleft ... ACPA’s 74th Annual Meeting. KLS is a longtime supporter of the event. , ... exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information Services ... Institute for Health and Care Excellence (NICE) framework. The agreement allows purchasers ... (NHS) to search, order and purchase medical and healthcare-related content through GOBI ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... DUBLIN , Feb 24, 2017 Research ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... provides drug pricing data and benchmarks in the global Urinary Incontinence ... What are the key drugs marketed for Urinary Incontinence ...
(Date:2/23/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device company ... the urology market, will release financial results for the ... before the market open on Thursday, March 9, 2017. ... call and webcast to discuss its financial results the ... a.m. Eastern Time (10:00 a.m. Central Time). Darin ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
Breaking Medicine Technology: